Obesity drug sales help Novo Nordisk beat expectations
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations. The company on Wednesday reported that net sales increased by 26 per cent year on year in 2024 to DKr290bn ($40bn),
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
News Medical on MSN18h
Can parents' diet predict childhood obesity? New research weighs inChildren’s eating habits are strongly influenced by their parents' weight status, with those having overweight or obese ...
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...
Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...
GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...
The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...
While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
A positive response to treatment for pediatric obesity has enduring health benefits into young adulthood, according to a study.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback